Perspectives
Patients with diabetes show poor adherence therapy for heart disease
Adherence to heart disease drugs dopped by half within one year, increasing risks
May 21, 2019Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes
This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.
- Glucagon like peptide-1 agonists (GLP-1)
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
- Dipeptidyl peptidase-4 inhibitors (DPP-4i)
All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90 percent in their clinical trials.)
Related news
Perspectives
June 1, 2023
Prime reimagines patient care, unites care team for a better experience and smarter treatment plan
The patient journey from a cancer diagnosis through treatment with multiple specialty medications…
Perspectives
May 30, 2023
Specialty Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
May 30, 2023
Traditional Drug Pipeline Update: May 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…